For integers a1, . . . , an > 0 and k > 1, let Lk+2(a1, . . . , an) denote the set of permutations of {1, . . . , a1 + · · · + an} whose descent set is contained in {a1, a1 + a2, . . . , a1+ · · ·+an−1}, and which avoids the pattern 12 . . . (k+2). We exhibit some bijections between such sets, most notably showing that #Lk+2(a1, . . . , an) is symmetric in the ai and is in fact Schur-concave. T...

6,463,329 B1 10/2002 Goedeke 6,667,725 B1 12/2003 Simons et al. 2001/0016683 A1 8/2001 Darrow et al. 2002/0027531 A1 3/2002 Brown et al. 2002/0042637 A1 4/2002 Stover 2002/0058906 A1 * 5/2002 Lebel et al. .................. 604/65 2002/0123777 A1 9/2002 Dolgin et al. 2002/0177884 A1 11/2002 Ahn et al. 2005/0267550 A1 * 12/2005 Hess et al. .................... 607/60 6,411,842 B1 * 6/2002 Cigain...

This note investigates πT,c1,c2(a1,a2)=P(supt∈[0,T](σ1B(t)−c1t)>a1,supt∈[0,T](σ2B(t)−c2t)>a2), where {B(t):t≥0} is a standard Brownian motion, with T>0,σ1,σ2>0,c1,c2∈R. We derive explicit formula for the probability πT,c1,c2(a1,a2) and find its asymptotic behavior both in so called many-source high-threshold regimes.

BACKGROUND Macrophage migration inhibitory factor (MIF) is released into the intraluminal fluid during bladder inflammation in the rat complexed to alpha1-inhibitor-3 (A1-I3; a rodent proteinase inhibitor in the alpha-macroglobulin family). The location of A1-I3 in the bladder had not been investigated. Therefore, we examined the location of A1-I3 and MIF/A1-I3 complexes in the bladder and chan...

Let h≥2 and let A=(A1,…,Ah) be an h-tuple of sets integers. For nonzero integers c1,…,ch, consider the linear form φ=c1x1+c2x2+⋯+chxh. The representation function RA,φ(n) counts number h-tuples (a1,…,ah)∈A1×⋯×Ah such that φ(a1,…,ah)=n. A is a φ-Sidon system multiplicity g if RA,φ(n)≤g for all n∈Z. every positive integer g, Fφ,g(n) denote largest q there exists withAi⊆[1,n]and|Ai|=q i=1,…,h. It ...

Parechovirus A1 (PeV-A1) often causes mild respiratory or gastrointestinal disease. Herein we report a case of acute heart failure due to dilated cardiomyopathy exacerbated by PeV-A1 infection in 10-month-old infant. He was brought our hospital with distress and compensated shock. Echocardiogram showed left ventricle severe mitral regurgitation, consistent cardiomyopathy. confirmed (1) positive...

Partial adenosine A1 receptor agonists with reduced intrinsic activity at the cardiovascular system would be promising for therapeutic application (e.g., as antilipolytic agents). In the present study a series of 8-alkylamino [methyl (M)-, ethyl (E)-, propyl (P)-, butyl (B)- and cyclopentyl (CP)-] derivatives of N6-cyclopentyladenosine (CPA) were investigated in conscious normotensive rats. Aft...

4,769,061 A 9/1988 Comai 4,810,648 A 3/1989 Stalker 4,940,835 A 7/1990 Shah et a1. 4,975,374 A 12/1990 Goodman et a1. 5,008,200 A 4/1991 Ranch et a1. 5,015,580 A 5/1991 Christou et al. 5,024,944 A 6/1991 Collins et a1. 5,266,317 A 11/1993 Tomalski et al. 5,322,783 A 6/1994 Tomes et a1. 5,494,813 A 2/1996 Hepher et a1. 5,563,055 A 10/1996 Townsend et al. 5,767,080 A * 6/1998 Beck et a1. ...........

Introduction: Ligands of adenosine A1Rs are potential candidates for the development drugs treatment paroxysmal supraventricular tachycardia, angina pectoris, hypertriglyceridemia, type 2 diabetes mellitus, neuropathic pain, and heart failure. At same time, there is a deficiency that can regulate functions A1 receptors. A number A1-antagonists at various stages clinical trials; other not very s...